NovaBridge (NBP) director Woo Ian Ying details options and RSUs in Form 3

Rhea-AI Filing Summary

NovaBridge Biosciences director Woo Ian Ying has filed an initial Form 3 disclosing equity awards tied to the company’s American Depositary Shares (ADSs). The filing lists a 2025 employee share option with an exercise price of 6.13, covering 15,850 underlying Ordinary Shares, and expiring on October 15, 2035. It also reports 17,310 restricted share units (RSUs), each representing a contingent right to receive one ADS, vesting in three equal annual installments on October 15, 2026, 2027 and 2028. The options vest in three equal annual installments beginning on the first anniversary of the October 15, 2025 grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Woo Ian Ying

Role Director

Type	Security	Shares	Price	Value
holding	2025 Employee Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 15,850 shares (Direct); Restricted Share Units — 17,310 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Number of underlying securities and exercise price expressed in terms of ADSs The option was granted on October 15, 2025. The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date. On October 15, 2025, the Reporting Person was granted 17,310 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over three years in equal annual installments on October 15, 2026, 2027 and 2028.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Woo Ian Ying

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	(3)	10/15/2035	Ordinary Shares(1)	15,850(2)	$6.13(2)	D
Restricted Share Units	(4)	(4)	Ordinary Shares(1)	17,310(2)	(4)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Number of underlying securities and exercise price expressed in terms of ADSs

3. The option was granted on October 15, 2025. The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date.

4. On October 15, 2025, the Reporting Person was granted 17,310 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over three years in equal annual installments on October 15, 2026, 2027 and 2028.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does NovaBridge Biosciences (NBP) director Woo Ian Ying report on Form 3?

Woo Ian Ying reports initial equity holdings, including a 2025 employee share option and restricted share units. The filing shows existing awards rather than new market trades, outlining exercise terms, expiration, and vesting schedules tied to NovaBridge Biosciences’ American Depositary Shares.

How many RSUs does Woo Ian Ying hold in NovaBridge Biosciences (NBP)?

Woo Ian Ying holds 17,310 restricted share units (RSUs), each representing a contingent right to receive one ADS. These RSUs vest in three equal annual installments on October 15, 2026, 2027 and 2028, subject to continued service and plan conditions.

What are the key terms of Woo Ian Ying’s 2025 employee share option at NovaBridge (NBP)?

The 2025 employee share option carries an exercise price of 6.13, expressed in terms of ADSs, and expires on October 15, 2035. It covers 15,850 underlying Ordinary Shares and vests in three equal annual installments starting one year after the October 15, 2025 grant date.

Does the NovaBridge Biosciences (NBP) Form 3 show any insider share purchases or sales?

The Form 3 lists holdings and award terms, not open-market purchases or sales. Transactions are classified as holdings with an unknown direction, indicating disclosure of existing options and RSUs rather than buy or sell activity in NovaBridge Biosciences shares.

How are NovaBridge Biosciences (NBP) Ordinary Shares related to ADSs in this Form 3?

The filing states that Ordinary Shares may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. It also notes that the number of underlying securities and the exercise price for the option are expressed in terms of ADSs for reporting purposes.